The impact of Daratumumab on transfusion service costs
Sign Up to like & getrecommendations! Published in 2019 at "Transfusion"
DOI: 10.1111/trf.15134
Abstract: Daratumumab (DARA) is a human IgG1κ monoclonal antibody directed against CD38, approved for the treatment of multiple myeloma. As CD38 is expressed on RBCs, DARA can interfere with pretransfusion testing. DARA interference can be negated… read more here.
Keywords: impact daratumumab; transfusion; service costs; transfusion service ... See more keywords